What test is most specific for diagnosing Charcot-Marie-Tooth disease?

Genetic Testing is Most Specific for Charcot-Marie-Tooth Disease

Genetic testing for established pathogenic mutations provides 100% specificity (no false positives) for diagnosing Charcot-Marie-Tooth disease, making it the most specific test available 1.

Why Genetic Testing Has Perfect Specificity

The American Academy of Neurology practice parameter, based on 6 Class I and 6 Class II studies, establishes that genetic testing for CMT demonstrates:

• Specificity: 100% (completely eliminates false positives)
• High sensitivity for known mutations
• Unequivocal results for established pathogenic mutations 1

This means when a pathogenic mutation is detected, the diagnosis is definitive—there are no false positives.

The Diagnostic Algorithm: How to Use Genetic Testing Most Efficiently

The key is using a stepwise, phenotype-guided approach rather than random testing:

Step 1: Perform Electrodiagnostic Studies (EMG/NCS)

Determine if the neuropathy is:

• Demyelinating (uniformly slowed nerve conduction velocities)
• Axonal (reduced amplitudes with relatively preserved velocities)
• Mixed

Step 2: Apply Tiered Genetic Testing Based on EDX Results

For Demyelinating CMT (CMT1):

• First-tier test: PMP22 duplication

  • Accounts for 70% of CMT1 cases 1
  • Yield of 54-80% when restricted to demyelinating phenotype 1
  • 76-90% of sporadic CMT1 cases 1

• Second-tier: GJB1 (Connexin 32) mutation testing

  • Accounts for 12% of all CMT cases 1
  • Consider especially if X-linked inheritance pattern or if pedigree is uninformative

• Third-tier: MPZ mutations (5%), PMP22 point mutations (2.5%) 1

For Axonal CMT (CMT2):

• First-tier test: MFN2 mutations

  • Accounts for 33% of CMT2 cases 1

• Second-tier: GJB1 mutations (can present with axonal phenotype)

• Third-tier: Other rare genes (NEFL, HSPB1, GARS, RAB7) 1

Critical Clinical Pearls

Family history is NOT required for genetic testing:

• 30% of CMT1A cases represent de novo mutations 1
• Absence of family history should not deter genetic testing in patients with classic CMT phenotype 1

The "classic CMT phenotype" includes:

• Distal symmetric weakness and atrophy
• Pes cavus foot deformity
• Absent deep tendon reflexes
• Distal sensory loss
• Progressive course
• Onset typically before age 50 (94.6% of mutation-positive cases) 2

Common Pitfalls to Avoid

1. Don't order broad genetic panels first in demyelinating CMT—start with PMP22 duplication testing alone, which is more cost-effective 3

2. Don't skip electrodiagnostic studies—they are essential for directing appropriate genetic testing and dramatically improve diagnostic yield 1

3. Don't assume negative family history excludes hereditary neuropathy—up to 90% of sporadic CMT1 cases have PMP22 duplication 1

4. Beware of atypical presentations—some patients with CMT mutations have minimal findings and don't fit the classic phenotype 4

Modern Testing Approaches

Recent evidence supports using multiplex ligation-dependent probe amplification (MLPA) for copy number variation detection (particularly PMP22 duplications/deletions) combined with targeted next-generation sequencing panels for point mutations 5, 6. This combined approach achieves diagnostic yields of 65-68% 5, 6.

The diagnostic odyssey averages 5.6 years in diagnosed patients 5, emphasizing the importance of early, appropriately directed genetic testing.

Bottom Line for Clinical Practice

Start with EMG/NCS to classify the neuropathy type, then proceed directly to PMP22 duplication testing for demyelinating forms or MFN2 mutation testing for axonal forms. This targeted approach maximizes diagnostic yield while minimizing cost and time to diagnosis 1, 2.